2025 年 42 巻 3 号 p. 203-204
In the clinical development of drugs in Neurology, there are clinical development issues such as the lack of established the efficacy endpoint, the number of patients is small, controlled comparative studies are difficult, and so on. Therefore, it is hoped that industry, government, and academia will collaborate to organize issues and ideas based on the knowledge of current scientific findings accumulated to date and formulate guidelines for clinical evaluation in drug development, so that drug development and review can be conducted appropriately and promptly.
